These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 27216181)

  • 41. Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma.
    Weinberger PM; Adam BL; Gourin CG; Moretz WH; Bollag RJ; Wang BY; Liu Z; Lee JR; Terris DJ
    Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):503-10. PubMed ID: 17515507
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
    Cui W; Sang W; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(7-8):673-80. PubMed ID: 22997967
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ImmunoPET imaging of phosphatidylserine in pro-apoptotic therapy treated tumor models.
    Ogasawara A; Tinianow JN; Vanderbilt AN; Gill HS; Yee S; Flores JE; Williams SP; Ashkenazi A; Marik J
    Nucl Med Biol; 2013 Jan; 40(1):15-22. PubMed ID: 23062948
    [TBL] [Abstract][Full Text] [Related]  

  • 44.
    McKnight BN; Viola-Villegas NT
    J Labelled Comp Radiopharm; 2018 Jul; 61(9):727-738. PubMed ID: 29341222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
    Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
    Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
    Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF
    Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 18FDG-positron emission tomography/computed tomography (PET/CT) scanning in thyroid nodules with nondiagnostic cytology.
    Giovanella L; Suriano S; Maffioli M; Ceriani L
    Clin Endocrinol (Oxf); 2011 May; 74(5):644-8. PubMed ID: 21470288
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnostic and prognostic role of HBME-1, galectin-3, and β-catenin in poorly differentiated and anaplastic thyroid carcinomas.
    Rossi ED; Straccia P; Palumbo M; Stigliano E; Revelli L; Lombardi CP; Santeusanio G; Pontecorvi A; Fadda G
    Appl Immunohistochem Mol Morphol; 2013 May; 21(3):237-41. PubMed ID: 23235344
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.
    Deri MA; Ponnala S; Kozlowski P; Burton-Pye BP; Cicek HT; Hu C; Lewis JS; Francesconi LC
    Bioconjug Chem; 2015 Dec; 26(12):2579-91. PubMed ID: 26550847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
    Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
    J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
    Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S
    APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
    Bartolazzi A; Bussolati G
    Histopathology; 2006 Jan; 48(2):212-3. PubMed ID: 16405677
    [No Abstract]   [Full Text] [Related]  

  • 53. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation.
    Kawachi K; Matsushita Y; Yonezawa S; Nakano S; Shirao K; Natsugoe S; Sueyoshi K; Aikou T; Sato E
    Hum Pathol; 2000 Apr; 31(4):428-33. PubMed ID: 10821488
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach.
    Vriens D; Adang EM; Netea-Maier RT; Smit JW; de Wilt JH; Oyen WJ; de Geus-Oei LF
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3263-74. PubMed ID: 24873995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies.
    Inohara H; Segawa T; Miyauchi A; Yoshii T; Nakahara S; Raz A; Maeda M; Miyoshi E; Kinoshita N; Yoshida H; Furukawa M; Takenaka Y; Takamura Y; Ito Y; Taniguchi N
    Biochem Biophys Res Commun; 2008 Nov; 376(3):605-10. PubMed ID: 18809382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correction: Noninvasive
    Cancer Res; 2017 Aug; 77(15):4204. PubMed ID: 28765379
    [No Abstract]   [Full Text] [Related]  

  • 57. Noninvasive small-animal imaging of galectin-1 upregulation for predicting tumor resistance to radiotherapy.
    Lai J; Lu D; Zhang C; Zhu H; Gao L; Wang Y; Bao R; Zhao Y; Jia B; Wang F; Yang Z; Liu Z
    Biomaterials; 2018 Mar; 158():1-9. PubMed ID: 29272764
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer.
    Greco A; Auletta L; Orlandella FM; Iervolino PLC; Klain M; Salvatore G; Mancini M
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ImmunoPET in oncology.
    Mulero F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(5):332-339. PubMed ID: 35961857
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biologic and Clinical Perspectives on Thyroid Cancer.
    Fagin JA; Wells SA
    N Engl J Med; 2016 Dec; 375(23):2307. PubMed ID: 27959677
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.